Management of kidney cancer: Canadian kidney cancer forum consensus update

Journal of the Canadian Urological Association

Volumn 3, Issue 3, 2009, Pages 200-204

  Jewett, Michael ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70450192692     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Canadian Cancer Society, National Cancer Institute of Canada. Canadian cancer statistics, 2008. Toronto: The Institute; 2008.
2. Canadian Kidney Cancer Forum. Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement. Can Urol Assoc J 2008;2:175-182
3. Kassouf W, Siemens R, Morash C, et al. Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma. Can Urol Assoc J 2008;3:73-76
4. Volpe A, Kachura JR, Geddie WR, et al. Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol 2007;178:379-386
5. Lane BR, Samplaski MK, Hertws BR, et al. Renal mass biopsy: a renaissance? J Urol 2008;179:20-27
6. Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006;7:735-40.
7. Thompson RH, Boorjian SA, Lohse CM, et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol 2008;179:472-473
8. Fergany AF, Hafez KS, Novick AC. Long trem results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol 2000;163:442-445
9. Becker F, Siemer S, Humke U, et al. Elective nephron sparing surgery should become standard treatment for small unilateral renal cell carcinoma: Long-term survival data of 216 patients. Eur Urol 2006; 49:308-313
10. Lesage K, Joniau S, Francis K, et al. Comparison between open partial and radical nephrectomy for renal tumours: perioperative outcome and health-related quality of life. Eur Urol 2007;51:614.
11. Wang AJ, Bhayani SB. Robotic partial nephrectomy versus laparoscopic partial nephrectomy for renal cell carcinoma: single-surgeon analysis of >100 consecutive procedures. Urology 2009;73:306-310
12. Ho H, Schwentner C, Neururer R, et al. Robotic-assisted laparoscopic partial nephrectomy: surgical technique and clinical outcomes at 1 year. BJU Int 2009;103:663-668
13. Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass: a metaanalysis. Cancer 2008;15:2671-2680
14. Leibovich BC, Blute ML, Cheville JC, et al. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004;171: 1066-1070
15. Peycelon M, Hupertan V, Comperat E, et al. Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm. J Urol 2009;181:35-41.
16. Gervais, DS, Arellano RS, McGovern FJ, et al. Radiofrequency ablation of renal cell carcinoma: part 2, lessons learned with ablation of 100 tumors. AJR Am J Roentgenol 2005; 85:72-80.
17. Zagoria RJ, Traver MA, Werle DM, et al. Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR Am J Roentgenol 2007;189:429-436
18. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: impact on survival and benefits of immunotherapy. Cancer 2003;97:2995-3002. (Pubitemid 36676253)
19. Leibovich BC, Blute ML. Lymph node dissection in the management of renal cell carcinoma. Urol Clin North Am 2008;208:673-678
20. Terrone C, Guercio S, De Luca S, et al. The number of lymph nodes examined and staging accuracy in renal cell carcinoma. BJU Inl 2003;91:37-40.
21. Motzer RJ, Basch E. Targeted drugs for metastatic renal cell carcinoma. Lancet 2007;370:2071-2073
22. Bukowski RM, Eisen T, Szczylik C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 2007;25(18S):5023.
23. Figlin R, Hutson TE, Tomczak P, et al., Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic RCC(mRCC). J Clin Oncol 2008;26:5024.
24. Heng DYC, Chi KN, Murray N, et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with mRCC. Cancer 2009;115;776-783
25. Warren, MA, Venner PM, North SA, et al. Then and now: The effect of tryrosine kinase inhibitors on survival in patients with metastatic renal cell carcinoma in Alberta, Canada. J Clin Oncol 2008;26:16033.
26. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281 (Pubitemid 46849157)
27. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134
28. Motzer RJ, Escudier B, Oudard S. Efficacy of evirolimus in advanced renal cell carcinoma:a double blind, randomized,placebo-controlled phase III trial. Lancet 2008;372:449-456
29. Gore ME, Porta C, Oudard S, et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol 2007;25 (18S):5010.
30. Dutcher JP, Szczylik C, Tannir N, et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 2007;25(18S):5033.
31. Knox JJ, Figlin RA, Stadler WM, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: safety and efficacy. J Clin Oncol 2007;25(18S):5011.
32. Cancer Care. Ontario Genitourinary Cancer Practice Guidelines. 2006. Available: www.cancercare.on.ca/toolbox/qualityguidelines/diseasesite/genito- ebs/ (accessed 2009 May 12).
33. Negrier S, Perol D, Ravaud A, et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007;110:2468-2477
34. Sablin MP, Bouaita L, Balleyguier C, et al. Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients. J Clin Oncol 2007;25(18S):5038.
35. Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179:81-86
36. Hott S. Guidelines for mRCC. In press.
37. Stadler WM, Figlin RA, Ernstof MS, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC). J Clin Oncol 2007;25(18S):5036.
38. Nanus DM, Garino A, Milowsky MI, et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004;101:1545-1551
39. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071-1076
40. Mickisch GH. Urologic approaches to metastatic renal cell carcinoma. Onkologie 2001;24:122-126